MENU

Leveraging Metabolites as Biomarkers for Personalized and Translational Medicine

Leveraging Metabolites as Biomarkers for Personalized and Translational Medicine

SPEAKER: Dr. Bryan Whittmann - Sr. Study Director, Metabolon, Inc.

Estimates vary, but the time and cost to successfully bring a drug to market are 12+ years and over a billion dollars. Much of this is due to a greater than 95% failure rate. Pharmaceutical researchers frequently cite a lack of “translatability” as the root cause of this failure. Overcoming translational barriers requires a deep understanding of human disease biology, and biomarkers are needed to precisely define the key aspects of different disease or response characteristics. Only then, the correct populations can be selected, the right targets pursued, and preclinical models that match key aspects of disease can be designed. This is at the heart of translational or precision medicine.

This brief webinar will first navigate through the landscape and challenges in discovering biomarkers suitable for precision and translational medicine. The journey continues as we explore the rationale for why a systematic, discovery metabolomics approach is practical for addressing such challenges. Next, we share examples of how the approach has been applied to various disease research programs and the impact it has made. Lastly, the webinar walks through a specific case study demonstrating the usefulness of metabolomics and its impact on the successful development and commercialization of an innovative diagnostic to measure insulin resistance.